Predictors of proteinuria reduction by monotherapy with an angiotensin receptor blocker, olmesartan

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 13, Issue 2, 2012, Pages 239-243

  Ono, Minamo ^a   Fukuda, Michio ^a   Miura, Toshiyuki ^a   Mizuno, Masashi ^a   Kato, Yoko ^a   Sato, Ryo ^a   Naito, Takehiro ^a   Togawa, Hiroyuki ^a   Sasakawa, Yuji ^a   Tomonari, Tatsuya ^a   Ichikawa, Tadashi ^a   Shirasawa, Yuichi ^a   Ito, Akinori ^a   Yoshida, Atsuhiro ^a   Kimura, Genjiro ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Blood pressure; chronic kidney disease (CKD); olmesartan; proteinuria; RAS inhibitors

Indexed keywords

OLMESARTAN; RENIN;

ADOLESCENT; ADULT; AGED; ALBUMINURIA; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG DOSE INCREASE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MALE; MONOTHERAPY; PATIENT SELECTION; PLASMA RENIN ACTIVITY; PREDICTOR VARIABLE; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ALBUMINURIA; ANGIOTENSIN RECEPTOR ANTAGONISTS; BLOOD PRESSURE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PROGNOSIS; PROTEINURIA; RENIN; TETRAZOLES; YOUNG ADULT;

EID: 84861862952     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320311434817     Document Type: Article

References (30)

1. Fukuda M, Munemura M, Usami T, et al. Nocturnal blood pressure is elevated with natriuresis and proteinuria as renal function deteriorates in nephropathy. Kidney Int. 2004 ; 65: 621-625 (Pubitemid 38130657)
2. Fukuda M, Yamanaka T, Mizuno M, et al. Angiotensin II type 1 receptor blocker, olmesartan, restores nocturnal blood pressure decline by enhancing daytime natriuresis. J Hypertens. 2008 ; 26: 583-588 (Pubitemid 351317269)
3. Kojima M, Dohi Y, Ohashi M, et al. Crucial role of kidney function in resistance to antihypertensive therapy in patients with diabetes mellitus. J Hypertens. 2010 ; 28: 2323-2328
4. Wühl E, Mehls O, Schaefer F. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int. 2004 ; 66: 768-776 (Pubitemid 38982021)
5. Kunz R, Friedrich C, Wolbers M, et al. Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008 ; 148: 30-48 (Pubitemid 351688350)
6. Crowe AV, Howse M, Vinjamuri S, et al. The antiproteinuric effect of losartan is systemic blood pressure dependent. Nephrol Dial Transplant. 2003 ; 18: 2160-2164 (Pubitemid 37220326)
7. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002 ; 106: 672-678 (Pubitemid 34851925)
8. Minutolo R, Balletta MM, Catapano F, et al. Mesangial hypercellularity predicts antiproteinuric response to dual blockade of RAS in primary glomerulonephritis. Kidney Int. 2006 ; 70: 1170-1176 (Pubitemid 44344089)
9. Praga M, Hernández E, Morales E, et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2001 ; 16: 1790-1798 (Pubitemid 32821410)
10. Price DA, Lansang MC, Osei SY, et al. Type 2 diabetes, obesity, and the renal response to blocking the renin system with irbesartan. Diabet Med. 2002 ; 19: 858-861 (Pubitemid 35177187)
11. Navis G, de Jong P, Donker AJ, et al. Diuretic effects of angiotensin-converting enzyme inhibition: comparison of low and liberal sodium diet in hypertensive patients. J Cardiovasc Pharmacol. 1987 ; 9: 743-748 (Pubitemid 17095578)
12. Gansevoort RT, de Zeeuw D, de Jong PE. Additive antiproteinuric effect of ACE inhibition and a low-protein diet in human renal disease. Nephrol Dial Transplant. 1995 ; 10: 497-504
13. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990 ; 86: 1343-1346 (Pubitemid 20370444)
14. Kurokawa K, Abe K, Saruta T, et al. Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis. J Renin Angiotensin Aldosterone Syst. 2002 ; 3: 167-175 (Pubitemid 35350785)
15. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002 ; 39 (2 Suppl. 1). S1 - S266
16. Fukuda M, Mizuno M, Yamanaka T, et al. Patients with renal dysfunction require a longer duration until blood pressure dips during the night. Hypertension. 2008 ; 52: 1155-1160
17. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 ; 42: 1206-1252 (Pubitemid 37553153)
18. Silkensen JR, Kasiske BL Brenner & Rector's The kidney. 7 th ed.Philadelphia: Saunders, 2004, pp.1123-1126. Brenner BM, ed. Philadelphia: Saunders ; 2004: 1123-1126.
19. Boersma C, Postma MJ, Visser ST, et al. Baseline albuminuria predicts the efficacy of blood pressure-lowering drugs in preventing cardiovascular events. Br J Clin Pharmacol. 2008 ; 65: 723-732 (Pubitemid 351545792)
20. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 ; 345: 861-869
21. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001 ; 345: 870-878
22. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 ; 345: 851-860
23. Haller H, Ito S, Izzo JL, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011 ; 364: 907-917
24. Brenner BM. Retarding the progression of renal disease. Kidney Int. 2003 ; 64: 370-378
25. Slataper R, Vicknair N, Sadler R, et al. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med. 1993 ; 153: 973-980 (Pubitemid 23124738)
26. Hebert LA, Bain RP, Verme D, et al. Remission of nephrotic range proteinuria in type I diabetes. Collaborative Study Group. Kidney Int. 1994 ; 46: 1688-1693 (Pubitemid 24370485)
27. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997 ; 349: 1857-1863
28. De Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004 ; 65: 2309-2320 (Pubitemid 38670018)
29. Atkins RC, Briganti EM, Lewis JB, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis. 2005 ; 45: 281-287 (Pubitemid 40431053)
30. Berthoux F, Mohey H, Laurent B, et al. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol. 2011 ; 22: 752-761